Placement: Duke University
Mentor: Mark McClellan, M.D., Ph.D. (Director, Duke-Margolis Center for Health Policy and Robert J. Margolis, MD, Professor of Business, Medicine and Policy, Duke University)
Co-mentors: Gregory Daniels, Ph.D., M.P.H., R.Ph. (Deputy Director, Duke-Margolis Center for Health Policy and Clinical Professor, Fuqua School of Business, Duke University)
Rita Redberg, M.S., M.D. (Professor, Department of Medicine, University of California, San Francisco)
Project: Financing (new) Technologies: Balancing Access, Safety, Quality and Expenditures in Health Care Systems
Cornelia Henschke, Ph.D., M.Sc., is a 2018–19 German Harkness/B. Braun Stiftung Fellow in Health Care Policy and Practice. She is currently the Head of the Research Group MeDIoRI (Medical Devices: Incentives and Impact of Regulatory Instruments) and the Deputy Head of the Berlin Centre of Health Economics Research at the Department of Health Care Management, Berlin University of Technology. Her research focuses on investigating the effects of policies on pricing, access and quality of care, especially in the context of health technologies. Henschke’s recent work is on medical devices, pharmaceuticals, and emergency care, and she regularly collaborates with diverse stakeholders from science, policy, self-governing bodies, regulatory institutions and industry. In addition to her peer-reviewed publications in journals such as Health Policy and the International Journal of Health Technology Assessment, she has co-authored policy-relevant reports, e.g. for the German Federal Ministry of Health on fostering research and development in the field antimicrobial resistance. This report was used as a background paper for the 2015 G7 Health Ministers' Meeting in Berlin. Henschke received her Ph.D. in economics and a Diploma’s degree in business administration with special emphasis on health care management from the Berlin University of Technology.
Project Abstract: Medical technologies have contributed to substantial improvements in health outcomes, but may also harm patients. Both the U.S. and Germany struggle with high health care expenditures, for which technologies are a contributing factor. Therefore, instruments and measures such as innovation payments and the systematized gathering and evaluation of real world evidence, are used to ensure the delivery of effective health care and to regulate the diffusion of technologies. In the U.S., several novel mechanisms have been implemented to promote the quality and effectiveness of care, and control utilization patterns and costs.
Part one of this project will use claims data and stakeholder interviews to explore Medicare’s ‘new technology add-on payment’ (NTAP) program and its effects on hospitals’ utilization of related technologies. Part two will investigate projects of the National Evaluation System for Health Technology Coordinating Center (NESTcc) that have been developed through an innovative framework for gathering real-world evidence to foster the provision of safe and effective care with medical devices. The framework’s suitability for the German/European context, and whether insurers could make use of NESTcc activities to support value-based decision-making, will also be explored.
Harkness-Related Publications:
C. Henschke, R. Redberg. Medical Device Price Differentials In The U.S. And Europe – Rethinking Price Regulation? Health Affairs. 2018.